Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics
Objective This study aims to assess the clinical efficacy and safety of CHF-II in combination with RG for treating AKI on CKD (A on C), and to explore potential therapeutic mechanisms through lipidomics analysis.Methods 98 patients were enrolled and randomly assigned to the RG or RG + CHF groups. Bo...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2356021 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591090270601216 |
|---|---|
| author | Ling Chen Qian Wang Tonglu Li Lejia Li Chen Wang Bing Xu Xuezhong Gong |
| author_facet | Ling Chen Qian Wang Tonglu Li Lejia Li Chen Wang Bing Xu Xuezhong Gong |
| author_sort | Ling Chen |
| collection | DOAJ |
| description | Objective This study aims to assess the clinical efficacy and safety of CHF-II in combination with RG for treating AKI on CKD (A on C), and to explore potential therapeutic mechanisms through lipidomics analysis.Methods 98 patients were enrolled and randomly assigned to the RG or RG + CHF groups. Both groups received RG therapy, with RG + CHF group additionally receiving CHF-II treatment over a duration of two weeks. Evaluation endpoints included changes in renal function, blood lipid profiles, urinary AKI biomarkers, and TCM symptoms before and after treatment. Serum samples were collected for lipid metabolite analysis.Results The total clinical effective rate in RG + CHF group was 73.5%, and that of RG group was 40.8%. TCM syndrome scores in RG + CHF group showed a more pronounced decrease (p < 0.05). Scr, BUN, and UA levels decreased while eGFR levels increased in both groups (p < 0.05), with a greater magnitude of change observed in the RG + CHF group. Urinary AKI biomarkers decreased more in RG + CHF group (p < 0.05). No serious adverse events occurred during the trial. 58 different lipid metabolites and 48 lipid biomarkers were identified. According to the KEGG database, the possible metabolic pathways involved triglyceride metabolic pathway and fat digestion and absorption metabolic pathways.Conclusion CHF-II effectively alleviated kidney injury and improved TCM syndrome scores in patients with A on C. Lipid differential metabolites could serve as diagnostic indicators for AKI in patients with CKD. The possible metabolic pathways might be implicated in therapeutic action of CHF-II in the prevention and treatment of patients with A on C. |
| format | Article |
| id | doaj-art-44cc14e85f524848bfb5103f50317d48 |
| institution | Kabale University |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-44cc14e85f524848bfb5103f50317d482025-01-23T04:17:47ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146110.1080/0886022X.2024.2356021Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomicsLing Chen0Qian Wang1Tonglu Li2Lejia Li3Chen Wang4Bing Xu5Xuezhong Gong6Department of Nephrology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Nephrology, Minhang Branch of Yueyang Hospital of Integrative Chinese & Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Nephrology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaObjective This study aims to assess the clinical efficacy and safety of CHF-II in combination with RG for treating AKI on CKD (A on C), and to explore potential therapeutic mechanisms through lipidomics analysis.Methods 98 patients were enrolled and randomly assigned to the RG or RG + CHF groups. Both groups received RG therapy, with RG + CHF group additionally receiving CHF-II treatment over a duration of two weeks. Evaluation endpoints included changes in renal function, blood lipid profiles, urinary AKI biomarkers, and TCM symptoms before and after treatment. Serum samples were collected for lipid metabolite analysis.Results The total clinical effective rate in RG + CHF group was 73.5%, and that of RG group was 40.8%. TCM syndrome scores in RG + CHF group showed a more pronounced decrease (p < 0.05). Scr, BUN, and UA levels decreased while eGFR levels increased in both groups (p < 0.05), with a greater magnitude of change observed in the RG + CHF group. Urinary AKI biomarkers decreased more in RG + CHF group (p < 0.05). No serious adverse events occurred during the trial. 58 different lipid metabolites and 48 lipid biomarkers were identified. According to the KEGG database, the possible metabolic pathways involved triglyceride metabolic pathway and fat digestion and absorption metabolic pathways.Conclusion CHF-II effectively alleviated kidney injury and improved TCM syndrome scores in patients with A on C. Lipid differential metabolites could serve as diagnostic indicators for AKI in patients with CKD. The possible metabolic pathways might be implicated in therapeutic action of CHF-II in the prevention and treatment of patients with A on C.https://www.tandfonline.com/doi/10.1080/0886022X.2024.2356021Chuan Huang Fang-IIlipidomicsacute kidney injurychronic kidney diseasetherapeutic mechanisms |
| spellingShingle | Ling Chen Qian Wang Tonglu Li Lejia Li Chen Wang Bing Xu Xuezhong Gong Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics Renal Failure Chuan Huang Fang-II lipidomics acute kidney injury chronic kidney disease therapeutic mechanisms |
| title | Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics |
| title_full | Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics |
| title_fullStr | Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics |
| title_full_unstemmed | Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics |
| title_short | Exploring therapeutic mechanisms of Chuan Huang Fang-II in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics |
| title_sort | exploring therapeutic mechanisms of chuan huang fang ii in the treatment of acute kidney injury on chronic kidney disease patients from the perspective of lipidomics |
| topic | Chuan Huang Fang-II lipidomics acute kidney injury chronic kidney disease therapeutic mechanisms |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2356021 |
| work_keys_str_mv | AT lingchen exploringtherapeuticmechanismsofchuanhuangfangiiinthetreatmentofacutekidneyinjuryonchronickidneydiseasepatientsfromtheperspectiveoflipidomics AT qianwang exploringtherapeuticmechanismsofchuanhuangfangiiinthetreatmentofacutekidneyinjuryonchronickidneydiseasepatientsfromtheperspectiveoflipidomics AT tongluli exploringtherapeuticmechanismsofchuanhuangfangiiinthetreatmentofacutekidneyinjuryonchronickidneydiseasepatientsfromtheperspectiveoflipidomics AT lejiali exploringtherapeuticmechanismsofchuanhuangfangiiinthetreatmentofacutekidneyinjuryonchronickidneydiseasepatientsfromtheperspectiveoflipidomics AT chenwang exploringtherapeuticmechanismsofchuanhuangfangiiinthetreatmentofacutekidneyinjuryonchronickidneydiseasepatientsfromtheperspectiveoflipidomics AT bingxu exploringtherapeuticmechanismsofchuanhuangfangiiinthetreatmentofacutekidneyinjuryonchronickidneydiseasepatientsfromtheperspectiveoflipidomics AT xuezhonggong exploringtherapeuticmechanismsofchuanhuangfangiiinthetreatmentofacutekidneyinjuryonchronickidneydiseasepatientsfromtheperspectiveoflipidomics |